Analysts expect ImmunityBio, Inc. to report revenue of 61.80 M for Q3 26, against a range of 58.67 M to 64.93 M. The most recent reported quarter, Q2 26, came in at 51.24 M, a 7.1% beat against the 47.83 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 6.11 M | 7.55 M | 16.52 M | 26.43 M | 32.06 M | 38.28 M | 44.21 M | 51.24 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 3.26 M | 9.50 M | 16.22 M | 26.16 M | 33.05 M | 41.18 M | 44.74 M | 51.53 M | 64.93 M | 74.39 M | 78.62 M | 89.27 M | 139.11 M | 185.27 M | 210.15 M | 232.00 M | ||||||||||
| Low Estimate | 2.71 M | 8.47 M | 14.26 M | 22.39 M | 29.23 M | 37.29 M | 38.14 M | 44.12 M | 58.67 M | 62.16 M | 65.33 M | 73.97 M | 124.75 M | 169.88 M | 191.77 M | 194.26 M | ||||||||||
| Consensus Estimate | 2.99 M | 8.99 M | 15.24 M | 24.28 M | 31.14 M | 39.23 M | 41.44 M | 47.83 M | 61.80 M | 68.28 M | 71.97 M | 81.62 M | 131.93 M | 177.57 M | 200.96 M | 213.13 M |
Analysts expect ImmunityBio, Inc. to report earnings per share of -0.07 for Q3 26, against a range of -0.07 to -0.07. The most recent reported quarter, Q2 26, came in at -0.22, a 175.0% miss against the -0.08 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.14 | -0.09 | -0.15 | -0.10 | -0.07 | -0.06 | -0.62 | -0.22 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.15 | -0.18 | -0.13 | -0.11 | -0.10 | -0.08 | -0.07 | -0.08 | -0.07 | -0.06 | -0.08 | -0.08 | 0.05 | 0.08 | 0.01 | 0.12 | ||||||||||
| Low Estimate | -0.19 | -0.20 | -0.15 | -0.13 | -0.12 | -0.08 | -0.07 | -0.08 | -0.07 | -0.08 | -0.08 | -0.08 | 0.05 | 0.06 | 0.01 | 0.10 | ||||||||||
| Consensus Estimate | -0.17 | -0.19 | -0.14 | -0.12 | -0.11 | -0.08 | -0.07 | -0.08 | -0.07 | -0.07 | -0.08 | -0.08 | 0.05 | 0.07 | 0.01 | 0.11 |
Pull Wall Street consensus for ImmunityBio, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=IBRX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "IBRX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=IBRX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();